Compare TNDM & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNDM | DRTS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2013 | 2021 |
| Metric | TNDM | DRTS |
|---|---|---|
| Price | $16.46 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 5 |
| Target Price | ★ $28.55 | $17.80 |
| AVG Volume (30 Days) | ★ 2.1M | 441.6K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,014,736,000.00 | N/A |
| Revenue This Year | $5.69 | N/A |
| Revenue Next Year | $12.35 | $1,235.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $12.26 | $3.43 |
| 52 Week High | $29.65 | $15.79 |
| Indicator | TNDM | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 48.11 |
| Support Level | $14.54 | $13.73 |
| Resistance Level | $18.13 | $15.01 |
| Average True Range (ATR) | 1.04 | 0.57 |
| MACD | 0.07 | -0.09 |
| Stochastic Oscillator | 54.69 | 11.15 |
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.